Anticancer agent 242

• Description :

  Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) [1].

• CAS Number :

  [9007-83-4]

• UNSPSC :

  12352005

• Target :

  Biochemical Assay Reagents

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/anticancer-agent-242.html

• Smiles :

  FC1=C(F)C(SCCC2=CC=C(C(N3CCN(C(C4=CC=CC=C4C5=C(C=C/6)C(OC7=C5C=CC(N(CC)CC)=C7)=CC6=[N+](CC)\CC)=O)CC3)=O)C=C2)=C(F)C(NC8CCCCCCCCCCC8)=C1S(=O)(N)=O.[Cl-]

• Molecular Formula :

  C59H72ClF3N6O5S2

• Molecular Weight :

  1101.82

• References & Citations :

  [1]Niels V Heise, et al. Dehydroabietylamine-substituted trifluorobenzene sulfonamide rhodamine B hybrids as anticancer agents overcoming drug resistance. Eur J Med Chem. 2024 Jul 10:276:116667.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported